Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here


Payment Information We Accept Visa, Mastercard, American Express and Discover


By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Danilo Verge and David Kendall Join Zealand

Here is a brief preview of this blast: Zealand announced it has appointed Danilo Verge and David Kendall to lead the company's Medical Affairs organization. Verge, the former VP of AZ CVRM and VP of Novo Medical Affairs USA, will serve as Zealand's Head of Global Medical Affairs for Zealand's metabolic and gastrointestinal franchises (pictured bottom left; view LinkedIn profile). Kendall, former CMO at MannKind and VP of Lilly Global Medical Affairs, will serve as Senior Global Medical Advisor Metabolism (pictured bottom right; view LinkedIn profile). Below, FENIX provides thoughts on the new leadership in the context of Zealand's emerging commercial business as well as Verge and Kendall's moves.

About The Author

Matthew Maryniak

President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.